Androgenetic Alopecia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Androgenetic
alopecia, a condition with a genetic predisposition, is characterized by an
exaggerated response to androgens, affecting around 50% of both men and women.
It entails a gradual loss of scalp hair, typically commencing after puberty,
exhibiting a discernible pattern in both genders. Androgenetic alopecia
primarily stems from an overreaction to androgens, which triggers a shortened
growth phase (anagen) in the normal hair growth cycle, leading to follicular
miniaturization. Diagnosis usually relies on clinical assessment, considering a
history of gradual onset post-puberty and sometimes a family history of
baldness. Treatment options approved by the FDA for pattern baldness include
topical minoxidil and finasteride. These treatments necessitate consistent
application for at least 4 to 6 months before noticeable improvements are seen
and require ongoing, indefinite usage to maintain results. Unlike antiandrogen
agents, finasteride acts as a 5 alpha-reductase type 2 inhibitor. In the
management of pattern baldness in women, oral antiandrogens such as
spironolactone are frequently employed. However, for men utilizing
spironolactone, the occurrence of adverse effects such as gynecomastia,
decreased libido, and mild impotence is possible. It is imperative to engage in
thorough discussions with a healthcare provider regarding these potential side
effects when contemplating spironolactone therapy for pattern baldness in
individuals of either gender.
Thelansis’s “Androgenetic Alopecia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Androgenetic Alopecia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Androgenetic Alopecia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Androgenetic Alopecia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment